Clinical Trials Logo
  1. Home
  2. Helicobacter Pylori Infection
  3. NCT05493644
  4. Details
NCT05493644 Clinical Trial

A Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

Helicobacter Pylori Infection Clinical Trial

Official title:
A Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05493644
Other study ID # 2022-SDU-QILU-G808
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 1, 2022
Est. completion date December 31, 2023

Study information
Verified date August 2022
Source Shandong University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The patients who accepted the quadruple eradication program of the helicobacter pylori but failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication time of helicobacter pylori.

Description:

Helicobacter pylori (HP) infection is a common global infectious disease, which is an important cause of chronic gastritis, peptic ulcer and gastric cancer. At present, due to the non-standard Helicobacter pylori eradication program in clinical work, poor patient compliance and other reasons, the phenomenon of HP eradication treatment failure is more and more common. However, there is still no conclusion on the most appropriate time for remedial treatment inpatients with Hp eradication failure.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 660
Est. completion date December 31, 2023
Est. primary completion date August 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Patients aged 18-70 with H. pylori infection. - Patients with previous Helicobacter pylori eradication. Exclusion Criteria: - Patients treated with H2-receptor antagonist, PPI, bismuth and antibioticsin the previous 4 weeks. - Patients with gastrectomy, acute GI bleeding and advanced gastric cancer. - Patients with known or suspected allergy to study medications. - Currently pregnant or lactating. - Inability to provide informed consent and other situations that couldinterfere with the examination or therapeutic protocol.

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Remedial treatment within 3 months
Remedial therapy was performed within 3 months
• Remedial treatment within 3 to 6 months
Remedial therapy was performed within 3 to 6 months
• Remedial treatment within 6 to 12 months
Remedial therapy was performed within 6 to 12 months
• Remedial treatment after 12 months
Remedial therapy was performed after 12 months

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Shandong University

Outcome
Type Measure Description Time frame Safety issue
Primary The most suitable re-eradication time The most suitable re-eradication time#The unit is month# will be assessed by paired comparison method . 12 months
Secondary Eradication rates in three groups Both intention to treat(ITT) and per-protocol(PP) analyses will be used for the assessment of the eradication rates of Helicobacter pylori infections in three groups 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05061732 - Helicobacter Pylori Eradication and Follow-up Phase 4
Completed NCT03779074 - Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies Phase 3
Completed NCT06076681 - A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules Phase 1/Phase 2
Recruiting NCT05329636 - Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy Phase 1/Phase 2
Recruiting NCT05065138 - Comparison of Helicobacter Pylori Eradication Effect Before and After Training of Gastroenterologists N/A
Completed NCT05049902 - Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication Phase 4
Not yet recruiting NCT06200779 - Tailored vs. Empirical Helicobacter Pylori Infection Treatment Phase 4
Not yet recruiting NCT06037122 - Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication
Completed NCT04617613 - Comparing Different Regimens for Eradication of Helicobacter Pylori in Kuwait Phase 4
Withdrawn NCT02552641 - Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Phase 4
Completed NCT02873247 - Standardize Communication With General Practitioner & Patient for Improved Eradication of Helicobacter Pylori
Completed NCT02557932 - Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication Phase 3
Recruiting NCT02249546 - Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection Phase 4
Completed NCT01933659 - Anti-H. Pylori Effect of Deep See Water Phase 3
Unknown status NCT01464060 - 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Phase 4
Completed NCT00841490 - Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults N/A
Recruiting NCT05728424 - One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL Phase 3
Recruiting NCT05549115 - Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection N/A
Recruiting NCT05997433 - Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori（SHARE2302) N/A
Completed NCT04708405 - The Relationship Between Helicobacter Pylori Infection and Inflammatory Bowel Diseases: A Real-life Observation